#South Korea #Seoul #Infectious Diseases #Seegene #STAgora

Seegene Unveils STAgora™: Revolutionizing Infectious Disease Analysis

In a groundbreaking announcement, Seegene Inc., the global leader in molecular diagnostics (MDx), revealed its latest innovation: STAgora™, a next-gen platform aimed at transforming the way infectious diseases are analyzed and managed worldwide. This cutting-edge platform is designed as a real-time infectious disease intelligence system, synthesizing diagnostic data with advanced statistical modeling methodologies.

The Vision Behind STAgora™

Following the challenges posed by the COVID-19 pandemic, Seegene recognized the need for efficient tools that allow for quick detection and monitoring of infectious disease outbreaks. STAgora™ sets out to redefine how public health officials identify, track, and respond to disease outbreaks across various regions. By visualizing real-time data from diagnostic tests, it creates a comprehensive understanding of infection trends at local, national, and continental levels.

Key Features and Capabilities

STAgora™ provides healthcare professionals with immediate, structured diagnostic reports and statistical analyses formatted for practical use. With customizable dashboards and real-time alerting functions, it empowers users to monitor outbreaks effectively. Additionally, the platform enables the tracking of individual cases and localized disease outbreaks, enhancing situational awareness and informing timely public health responses through data-driven insights.

The platform is built upon over 40 integrated statistical tools that facilitate early detection of unusual pathogenic patterns. Furthermore, it supports predictive modeling for seasonal trends and emerging disease outbreaks. These tools encompass modules for monitoring specific infections, analyzing co-infections based on symptoms, and computing real-time infection rate trends. Together, they convert static data into actionable intelligence, guiding proactive public health interventions.

Unlike traditional outbreak monitoring systems that rely on retrospective data, STAgora™ leverages real-time diagnostic information gathered from PCR technologies. This capability allows users to gain immediate insight into pathogen spread, predicting potential future outbreaks through AI-driven algorithms.

A Unique Architectural Approach

According to Young-Seag Baeg, Seegene's Head of Strategic Planning, what sets STAgora™ apart is its unique architecture that aggregates diagnostic data from around the globe into a unified analytical platform. Coupled with Seegene’s patented syndromic quantitative PCR technology, STAgora™ delivers enhanced insights into infections caused by single pathogens and simultaneous co-infections with multiple pathogens.

This comprehensive diagnostic overview enables healthcare providers to make quicker and more informed decisions at the point of care, ultimately benefiting patient outcomes and public health strategies.

Addressing Complex Health Threats

As stated by Daniel Shin, Executive Vice President and Chief Global Business and Marketing Officer at Seegene, the pandemic underscored the importance of accurate and timely interpretation of diagnostic data in shaping public health guidelines. With the increasing complexities posed by antimicrobial resistance, viral mutations, and co-infections, the ability to interpret diagnostic data effectively is now a cornerstone of clinical innovations and a crucial component of global health security.

Launching STAgora™ at ADLM 2025

Seegene will officially showcase STAgora™ at the 2025 Annual Meeting of the Association for Diagnostics and Laboratory Medicine (ADLM), scheduled from July 27 to 31 in Chicago, USA. This event will highlight the platform's core capabilities, including its integration with Seegene’s fully automated PCR system, CURECA™. The ADLM 2025 exhibition serves as a stepping stone for Seegene to explore potential global collaborations and partnerships with healthcare leaders and clients.

With the launch of STAgora™, Seegene aims to lay the foundation for a smarter, faster, and more interconnected global health security system. By combining real-time molecular diagnostics, AI-enhanced analytics, and global data integration, STAgora™ represents a strategic advancement toward building an intelligent public health infrastructure capable of proactively responding to emerging health threats. The company envisions this platform as a fundamental pillar of a global infectious disease response framework, signaling a leap forward in ensuring better diagnostic oversight and preparedness.

About Seegene

For over two decades, Seegene has specialized in research and development, manufacturing, and commercialization of syndromic PCR technologies. This expertise was particularly spotlighted during the COVID-19 pandemic when Seegene delivered over 340 million COVID-19 tests to more than 100 countries worldwide. The hallmark of Seegene’s syndromic PCR technology is its capability to simultaneously test for 14 pathogens causing similar clinical manifestations in a single tube, providing quantitative insights.

About CURECA™

CURECA™ (Continuous, Unlimited, Random-access, Expandable, and Customizable Automation) is a fully automated, modular PCR system that eliminates manual processes, allowing continuous real-time testing. This unified platform is designed to operate seamlessly, 24/7, without requiring human intervention. Its foundational component is CPS, the world’s first automated pre-processing system capable of handling a wide range of sample types, including blood, stool, sputum, and urine. CURECA™, tailored for both centralized and decentralized laboratories, offers scalable automation and flexible deployment, making it particularly valuable in resource-limited settings.

For further information, visit Seegene.com and follow linkedin.com/company/seegene-inc.